TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30314281

Group type: EXPERIMENTAL
Intervention: Fatty fish (herring/mackerel)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Meat (chicken/lamb/beef)
Number of subjects: 232
Study: 27017490

Group type: EXPERIMENTAL
Intervention: Extended EI (3-year EI)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Step-down psychiatric care (SC, 2-year EI)
Number of subjects: 160
Study: 26075288

Group type: EXPERIMENTAL
Intervention: Combined exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 23640971

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 20739792

Group type: EXPERIMENTAL
Intervention: Albendazole for 1 week (group A, n=58)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Albendazole for 4 weeks (group B, n=62)
Number of subjects: 120
Study: 17634183

Group type: EXPERIMENTAL
Intervention: Continuous budesonide (400 microg twice daily for 1 month, 200 microg twice daily for months 2‐6, 100 microg twice daily for months 7‐18)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Budesonide as needed (identical treatment to group 1 during months 1‐6, then budesonide for exacerbations as needed for months 7‐18)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG) 10 mg three times daily for months 1‐18
Number of subjects: 176
Study: 16420563

Group type: EXPERIMENTAL
Intervention: Pro12Ala polymorphism in the peroxisome proliferator activated-receptor gamma gene
Number of subjects: 2615

Group type: EXPERIMENTAL
Intervention: Thr164Ile polymorphism in the beta-2 adrenergic receptor gene
Number of subjects: 2615

Group type: EXPERIMENTAL
Intervention: Ala23Thr polymorphism in the eotaxin gene
Number of subjects: 2615
Study: 14693301

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/d
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/d
Number of subjects: 838

Group type: COMPARATOR
Intervention: Fluvastatin 20 mg/d
Number of subjects: 838

Group type: COMPARATOR
Intervention: Fluvastatin 40 mg/d
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Lovastatin (both dosages)
Number of subjects: 838
Study: 11044537

Group type: EXPERIMENTAL
Intervention: Dalteparin 5000 IU daily (prophylactic dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Adjusted-weight dalteparin therapeutic dose of 100 IU/kg twice daily
Number of subjects: 48
Study: 8793697

Group type: EXPERIMENTAL
Intervention: History of treated hypertension
Number of subjects: 11483

Group type: COMPARATOR
Intervention: No history of treated hypertension
Number of subjects: 11483
Study: 8227722

Group type: EXPERIMENTAL
Intervention: Regional anticoagulation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low dose pre‐filter heparin
Number of subjects: 64

Group type: COMPARATOR
Intervention: No anticoagulation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: CVVHD without anticoagulation
Number of subjects: 64
Study: 3955779

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g daily (1st trial)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Cefotaxime 2g twice daily (1st trial)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1g once daily (2nd trial)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g single daily (1st trial)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Cefotaxime
Number of subjects: 62
Study: 30078506

Group type: EXPERIMENTAL
Intervention: Individualized adjuvant treatment based on a molecular‐integrated risk profile
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard adjuvant treatment; vaginal brachytherapy
Number of subjects: 50
Study: 26724694

Group type: EXPERIMENTAL
Intervention: Measurement-based antidepressant management
Number of subjects: 0
Study: 24853781

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication
Number of subjects: 169

Group type: COMPARATOR
Intervention: No antihypertensive medication
Number of subjects: 169
Study: 22153787

Group type: EXPERIMENTAL
Intervention: Trimethoprim (TMP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TMP
Number of subjects: 10
Study: 20932395

Group type: EXPERIMENTAL
Intervention: Preformed metal crowns (Hall technique)
Number of subjects: 48
Study: 18594928

Group type: EXPERIMENTAL
Intervention: Iodopovidone pleurodesis via conventional (32F) chest tube (group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Iodopovidone pleurodesis via small-bore catheter (group 2)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Overall response rates for both groups
Number of subjects: 41

Group type: COMPARATOR
Intervention: Complication rates for both groups
Number of subjects: 41
Study: 16288147

Group type: EXPERIMENTAL
Intervention: Maternal education program based on the temperament theory
Number of subjects: 94
Study: 12902100

Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 10578215

Group type: EXPERIMENTAL
Intervention: Advice to eat more fish (2 portions of fatty fish each week)
Number of subjects: 2033
Study: 8678389

Group type: EXPERIMENTAL
Intervention: 15 micrograms of rgp 120 in MF59
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 50 micrograms of rgp 120 in MF59
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 50 micrograms of rgp 120 in MF59 plus 50 micrograms of MTP-PE
Number of subjects: 49

Group type: COMPARATOR
Intervention: MF59 alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 5 monthly injections of 50 micrograms of rgp 120 in MF59
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: gp120
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CD8+ cytotoxic T-lymphocyte activity
Number of subjects: 49
Study: 1878267

Group type: EXPERIMENTAL
Intervention: 10 minute booking intervals (experimental sessions)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual booking intervals of 7.5 to 5.0 minutes (control sessions)
Number of subjects: 16
Study: 6364329

Group type: EXPERIMENTAL
Intervention: 2000 mg metronidazole as a single dose on the first and third days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 2000 mg metronidazole as a single dose
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 400 mg metronidazole 2 times daily for 7 days
Number of subjects: 63
Study: 30892292

Group type: COMPARATOR
Intervention: Pink- neck implant
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pink abutment
Number of subjects: 40
Study: 29508120

Group type: EXPERIMENTAL
Intervention: Responses from 2011 cohort (185 participants)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Responses from 2000 cohort (259 participants)
Number of subjects: 444
Study: 27050869

Group type: EXPERIMENTAL
Intervention: Testosterone (100 mg testosterone gel daily for 6 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (placebo gel daily for 6 months)
Number of subjects: 64
Study: 25064150

Group type: EXPERIMENTAL
Intervention: X‐STOP device implantation
Number of subjects: 542

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 542
Study: 21752862

Group type: EXPERIMENTAL
Intervention: Volitional planning and self‐efficacy intervention
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Motivational skin cancer prevention approach
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 205
Study: 19580469

Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 18081899

Group type: EXPERIMENTAL
Intervention: Hydrophilic acrylic IOL (BL27)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hydrophobic acrylic IOL (SA60AT)
Number of subjects: 120
Study: 16156113

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS applied to upper outer arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS applied to chest
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl PCTS applied to lower inner arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl 40 microg via PCTS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl HCl 120 microg intravenously
Number of subjects: 0
Study: 12022894

Group type: EXPERIMENTAL
Intervention: Metronidazole for 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9935021

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) imaging
Number of subjects: 13
Study: 7578653

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion followed by yohimbine 0.4 mg/kg IV
Number of subjects: 11

Group type: COMPARATOR
Intervention: Yohimbine 0.4 mg/kg IV alone
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control tests (not specified)
Number of subjects: 11
Study: 2309513

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 0
Study: 6782251

Group type: EXPERIMENTAL
Intervention: Intravesical thio-tepa (30 mg or 60 mg) for ablation
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Intravesical thio-tepa (30 mg or 60 mg) for prophylaxis
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (no thio-tepa prophylaxis)
Number of subjects: 188
Study: 29799332

Group type: EXPERIMENTAL
Intervention: Dialogue intervention
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 28486720

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 110

Group type: COMPARATOR
Intervention: WFG LASIK
Number of subjects: 110
Study: 24195918

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Balance and tone classes
Number of subjects: 0
Study: 23329534

Group type: EXPERIMENTAL
Intervention: Radiofrequency Coagulation (RFC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined Hemorrhoidal Radiocoagulation (CHR)
Number of subjects: 30
Study: 20413453

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg/d for 8 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aliskiren administered alone or in combination with verapamil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aliskiren and verapamil combination
Number of subjects: 18
Study: 19152689

Group type: EXPERIMENTAL
Intervention: Exercise therapy with manual therapy
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exercise therapy only
Number of subjects: 150

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 150
Study: 17426180

Group type: EXPERIMENTAL
Intervention: Single dose oral mebendazole 500 mg
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Triple dose mebendazole
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Single dose albendazole
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Triple dose albendazole
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study: 15247138

Group type: EXPERIMENTAL
Intervention: Difluoromethylornithine (DFMO) at a dosage of 0.5 g/m(2)/d for approximately 13 weeks (cumulative dose of 45 g/m(2))
Number of subjects: 1
Study: 11465013

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine (an SSRI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: SSRIs (general)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 0
Study: 9571599

Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta‐estradiol at a dose of 50 micrograms per 24 h for 18 days followed by 10 days of combined treatment with medroxyprogesterone acetate (MPA) 5 mg orally
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens orally for 18 days followed by a combined treatment with MPA for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7924783

Group type: EXPERIMENTAL
Intervention: Indwelling catheters (Insuflon) for insulin injections
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard insulin injections (without Insuflon)
Number of subjects: 16
Study: 3050858

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 3801

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3801
Study: 31095127

Group type: EXPERIMENTAL
Intervention: Physical exercise therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional correction methods
Number of subjects: 60
Study: 28189404

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) for TKA
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard approach for TKA
Number of subjects: 66
Study: 25148382

Group type: EXPERIMENTAL
Intervention: Generic tacrolimus (Tacni)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Original tacrolimus (Prograf)
Number of subjects: 28
Study: 23441068

Group type: EXPERIMENTAL
Intervention: NEVO stent
Number of subjects: 47

Group type: COMPARATOR
Intervention: Xience stent
Number of subjects: 47
Study: 21837439

Group type: EXPERIMENTAL
Intervention: Vision of one's hand during movement planning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Virtual representation of one's initial hand location
Number of subjects: 0
Study: 17418849

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol+cyproterone acetate 50mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: conjugated estrogen+CA 50 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: ethinyl estradiole+CA 2mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: EE+CA 52 mg
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: EE+desogestrel
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Synthetic estrogens (EE)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 106
Study: 17174226

Group type: EXPERIMENTAL
Intervention: Olive oil (60 mL, fresh and deep-fried)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Soybean oil (60 mL, fresh and deep-fried)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Palm oil (60 mL, fresh and deep-fried)
Number of subjects: 10
Study: 15353497

Group type: EXPERIMENTAL
Intervention: Ramipril therapy
Number of subjects: 9297

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study: 11444677

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 35

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 35
Study: 9761803

Group type: EXPERIMENTAL
Intervention: Chiropractic manipulation
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 321

Group type: COMPARATOR
Intervention: Minimal intervention (educational booklet)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Physical therapy and chiropractic manipulation
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Therapy groups (physical therapy and chiropractic)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Educational booklet
Number of subjects: 321
Study: 7942982

Group type: EXPERIMENTAL
Intervention: Glyburide at bedtime
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo at bedtime
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Glyburide in the morning
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bedtime dosing of glyburide
Number of subjects: 32
Study: 3360159

Group type: EXPERIMENTAL
Intervention: Bulbocavernosus muscle graft (14 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Local repair without graft (9 patients)
Number of subjects: 20
Study: 31421233

Group type: EXPERIMENTAL
Intervention: Consistent stimulant medication use (n=53, 9%)
Number of subjects: 579
Study: 30577834

Group type: EXPERIMENTAL
Intervention: Multi-faceted educational and care-process-based intervention designed to improve guideline-concordant care of patients with BPPV.
Number of subjects: 0
Study: 27583368

Group type: EXPERIMENTAL
Intervention: MVA prime, sequential gp140 protein boost (M/M/P/P)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: DNA prime, concurrent MVA/gp140 boost (D/D/MP/MP)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: DNA prime, sequential MVA boost (D/D/M/M)
Number of subjects: 184

Group type: COMPARATOR
Intervention: MVA
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: DNA
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 184
Study: 25091716

Group type: EXPERIMENTAL
Intervention: Private insurance
Number of subjects: 219

Group type: COMPARATOR
Intervention: Public insurance
Number of subjects: 219
Study: 22083331

Group type: EXPERIMENTAL
Intervention: Single-Incision Laparoscopic Cholecystectomy (SILC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Four-Port Laparoscopic Cholecystectomy (4PLC)
Number of subjects: 200
Study: 20060082

Group type: EXPERIMENTAL
Intervention: 150 mg monthly oral ibandronate
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 18713883

Group type: EXPERIMENTAL
Intervention: Aprotinin (20,000 KIU/kg after induction of anesthesia, followed by 20,000 KIU/kg added to pump prime)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 50
Study: 15713520

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Gemcitabine (VG)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Vinorelbine plus Gemcitabine plus Cisplatin (VGP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Lung Cancer Symptom Scale (VG vs VGP)
Number of subjects: 86
Study: 11966736

Group type: EXPERIMENTAL
Intervention: IGF-I (10 ng/ml)
Number of subjects: 27

Group type: COMPARATOR
Intervention: GH (1000, 5000, or 50000 ng/ml)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: GH (200 and 5000 ng/ml) and IGF-I (10 ng/ml) for 24 and 48 h
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High IGFBP-3 levels
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Enhanced mitogenic response to IGF-I in vitro
Number of subjects: 27
Study: 10416910

Group type: EXPERIMENTAL
Intervention: Patients with ROSC
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Patients without ROSC
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control subjects (normal healthy volunteers)
Number of subjects: 26
Study: 8630864

Group type: EXPERIMENTAL
Intervention: Screening arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening arm
Number of subjects: 0
Study: 2205455

Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine (500 mg three times a day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 380039

Group type: EXPERIMENTAL
Intervention: Rimazolium
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study: 31809439

Group type: EXPERIMENTAL
Intervention: High-dose oral progesterone (400 mg twice daily for 3 days, then once daily until surgical abortion)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (twice daily for 3 days, then once daily until surgical abortion)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-dose oral progesterone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29746264

Group type: EXPERIMENTAL
Intervention: Aerobic‐resistance exercise intervention
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 154
Study: 28347572

Group type: EXPERIMENTAL
Intervention: Nefopam (20mg, six hourly)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Paracetamol (1g, six hourly)
Number of subjects: 72
Study: 25880303

Group type: EXPERIMENTAL
Intervention: Beyond Silence, a peer‐led program customized to the healthcare workplace
Number of subjects: 200

Group type: COMPARATOR
Intervention: Mental Health First Aid, a standardized literacy based training program
Number of subjects: 200
Study: 23949035

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study: 20803609

Group type: EXPERIMENTAL
Intervention: Relaxation response therapy (RRT)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Reiki therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 54
Study: 19626332

Group type: EXPERIMENTAL
Intervention: Oral anti-staphylococcal antibiotics for 3 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 17313507

Group type: EXPERIMENTAL
Intervention: Treatment of malaria and multivitamin supplementation
Number of subjects: 310
Study: 15197788

Group type: EXPERIMENTAL
Intervention: Logistic Regression (LR) model
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: Bayesian Regularization Multilayer Perceptron (BR‐MLP) model
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: Proportion of free PSA
Number of subjects: 1775
Study: 11318884

Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray, 20 mg
Number of subjects: 28
Study: 9848497

Group type: EXPERIMENTAL
Intervention: Soy protein as half of the daily protein intake
Number of subjects: 8
Study: 8135216

Group type: EXPERIMENTAL
Intervention: 1% TiF4 solution applied around brackets for 60 seconds
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 2909707

Group type: EXPERIMENTAL
Intervention: Oligoantigenic diet
Number of subjects: 63
Study: 871805

Group type: EXPERIMENTAL
Intervention: Breathing 30% oxygen during exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 or 4 litres of oxygen/minute from nasal prongs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Portable supply of liquid oxygen (Union Carbide Oxygen Walker)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wheeling the oxygen walker on a light-weight shopping trolley
Number of subjects: 0
Study: 31600474

Group type: EXPERIMENTAL
Intervention: Dose 6 and Dose Frequency 6
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dose 4 × Dose Frequency 9
Number of subjects: 34

Group type: COMPARATOR
Intervention: Dose 9 × Dose Frequency 4
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: All formats
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Individual differences in word learning
Number of subjects: 34